RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$65.93
+1.71%Oct 16, 2026, 12:00 UTC
Royalty Pharma plc approved a fourth-quarter 2026 dividend of $0.235 per Class A ordinary share.
Source:Oct 9, 2026, 12:50 UTC
Royalty Pharma announced that it will report its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open, and host a conference call and webcast at 8:00 a.m. Eastern Time.
Source:Sep 15, 2026, 20:35 UTC
Royalty Pharma announced a $7.5 million gift to Blood Cancer United to expand its Therapy Acceleration Program, a venture philanthropy initiative funding blood cancer therapies.
Source:Aug 12, 2026, 20:10 UTC
Royalty Pharma agreed to provide $100 million in funding to Zealand Pharma in exchange for economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera.
Source:Aug 5, 2026, 11:00 UTC
Royalty Pharma plc reported its financial results for the second quarter of 2026, with Portfolio Receipts growth of 6% to $773 million and Royalty Receipts growth of 14%, and raised its full year 2026 guidance for Portfolio Receipts to $3,400 million to $3,500 million.
Jul 17, 2026, 20:15 UTC
Royalty Pharma's board approved a third-quarter 2026 dividend of $0.235 per Class A ordinary share.
Source: